Generated by AI
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer. The company’s current programs center on novel approaches that engage the immune system, including its Boltbody Immune-Stimulating Antibody Conjugate platform and myeloid-directed antibodies designed to activate tumor-fighting immune responses. Its pipeline includes candidates that target specific cancer markers and tumor biology, reflecting a focus on precision immuno-oncology rather than broad, traditional chemotherapy. Bolt Biotherapeutics works within the biotechnology and cancer treatment markets, where it contributes to the development of targeted therapies intended to address unmet needs in oncology. Based in Redwood City, California, the company operates as a public biotech enterprise with a research and development model centered on advancing experimental cancer treatments through clinical evaluation.
Website900 Chesapeake Drive
Redwood City, CA, 94063
United States
The latest articles about BOLT.
Summary of Oct 26's posts. Generated by AI.
Summary of Oct 23's posts. Generated by AI.
Summary of Oct 23's posts. Generated by AI.
Summary of Oct 26's posts. Generated by AI.
Investors talking about BOLT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.